IRA implementation, Medicare & Medicaid payment and coverage issues
IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization
Federal budget issues
Duration: April 1, 2018
to
present
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations
Spending: about $1,640,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC)
Related Foreign Entities:
Roche Group (CH-4070 Basel, SUI); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Raissa Downs Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
Jennifer Young Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance
Michelle Easton Chief Health Counsel, Sen. Cmte. on Finance; Staff Dir., Senate Aging Cmte.; Leg. Asst., Congressman Billy Tauzin
Elizabeth Murray Senior Policy Advisor, Democratic Whip Steny Hoyer; Legislative Asst. for Rep. Mike Thompson, Rep. Bob Matsui, and Senator Bob Graham
Charlotte Ivancic Leg. Counsel, Sen. Jim DeMint; Health Counsel, Maj. Leader Bill Frist; Counsel and Budget Analyst, House Budget Cmte.; Asst. to the Speaker for Policy, Speaker John Boehner
Pamela Smith Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun
Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept. of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept. of Justice; Counsel and LA, Senator Carol Moseley-Braun
Emily Murry Staff Dir., Sub. Cmte. on Health, W&M Cmte; Sr. Policy Advisor, Majority Leader McCarthy; Policy Advisor, Majority Whip McCarthy; Professional Staff, Republican Study Cmte.; Leg. Aid, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price
Kimberly Brandt Sr. Counsel and Dir. External Affairs - HHS OIG; Prin. Dep. Administrator for Policy and Operations and Dir. of Medicare Program Integrity - CMS; Chief Oversight and General Counsel - Senate Cmte. on Finance
Margaret Joseph CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte.
Peter Fise Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform
Laura Friedel Leg. Asst., Sen. Zell Miller, Leg. Dir., Sen. Richard Shelby, Clerk, Staff Dir., Sen. Appropriations Committee
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on April 16.
Original Filing: 301550766.xml
Lobbying Issues
IRA implementation, Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on Jan. 17.
Original Filing: 301526630.xml
Lobbying Issues
IRA implementation, Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301515640.xml
Lobbying Issues
IRA implementation, Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
TARPLIN, DOWNS & YOUNG, LLC amended a lobbying report for representation of Genentech, Inc. in Q22023 on July 18, 2023.
Original Filing: 301479629.xml
Lobbying Issues
IRA implementation, Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on July 17, 2023.
Original Filing: 301478215.xml
Lobbying Issues
IRA implementation, Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3281 Transparent P.R.I.C.E Act
S.1339 the Pharmacy Benefit Manager Reform Act
IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on April 19, 2023.
Original Filing: 301459321.xml
Lobbying Issues
IRA implementation, Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
IRA implementation, drug pricing and access, transparency, 340B, drug safety
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on Jan. 19, 2023.
Original Filing: 301434603.xml
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
S. 4348, FDA Safety and Landmark Advancements Act
H.R. 7667, Food and Drug Amendments of 2022
H.R.2617, Consolidated Appropriations Act, 2023
drug pricing and access, transparency, covid, 340B, drug safety
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
H.R.2617, Consolidated Appropriations Act, 2023
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301414582.xml
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
S. 4348, FDA Safety and Landmark Advancements Act
H.R. 7667, Food and Drug Amendments of 2022
drug pricing and access, transparency, covid, 340B, drug safety
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
H.R. 6833, Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on July 19, 2022.
Original Filing: 301385303.xml
Lobbying Issues
H.R. 5376, the Build Back Better Act
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act
S. 4348, FDA Safety and Landmark Advancements Act
H.R. 7667, Food and Drug Amendments of 2022
drug pricing and access, transparency, covid, 340B, drug safety
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act
H.R. 2471, Consolidated Appropriations Act 2022
deficit reduction, reconciliation
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301367271.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 5376, the Build Back Better Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
H.R. 5376, the Build Back Better Act
no specific bills, drug pricing and access, transparency, covid
Agencies Lobbied
U.S. Senate
Lobbying Issues
deficit reduction, reconciliation
H.R. 5376, the Build Back Better Act
H.R. 2471, Consolidated Appropriations Act 2022
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325520.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 5376, the Build Back Better Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
H.R. 5376, the Build Back Better Act
no specific bills, drug pricing and access, transparency, covid
Agencies Lobbied
U.S. Senate
Lobbying Issues
deficit reduction, reconciliation
H.R. 5376, the Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on Oct. 19, 2021.
Original Filing: 301303041.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 1319, American Rescue Plan of 2021 implementation
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
H.R. 1319, American Rescue Plan of 2021 implementation
H.R. 3, The Lower Drug Costs Now Act
no specific bills, drug pricing and access, transparency, covid
Agencies Lobbied
U.S. Senate
Lobbying Issues
deficit reduction, reconciliation
S. Con. Res. 14
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
TARPLIN, DOWNS & YOUNG, LLC amended a lobbying report for representation of Genentech, Inc. in Q22021 on July 19, 2021.
Original Filing: 301281369.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 1319, American Rescue Plan of 2021 implementation
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
H.R. 1319, American Rescue Plan of 2021 implementation
no specific bills, drug pricing and access, transparency, covid
Agencies Lobbied
U.S. Senate
Lobbying Issues
deficit reduction
S. Con. Res. 5 (117)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on July 18, 2021.
Original Filing: 301279678.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 1319, The American Rescue Plan of 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
H.R. 1319, The American Rescue Plan of 2021
no specific bills, drug pricing and access, transparency, covid
Agencies Lobbied
U.S. Senate
Lobbying Issues
deficit reduction
S. Con. Res. 5 (117)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on April 18, 2021.
Original Filing: 301255444.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 1319, The American Rescue Plan of 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
H.R. 1319, The American Rescue Plan of 2021
no specific bills, drug pricing and access, transparency, flu season
Agencies Lobbied
U.S. Senate
Lobbying Issues
deficit reduction
S. Con. Res. 5 (117)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234870.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety, Operation Warp Speed
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
H.R. 6800 - The Heroes Act
H.R. 133 - Consolidated Appropriations Act, 2021
no specific bills, drug pricing and access, transparency, flu season
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 8337 - Continuing Appropriations Act of 2021
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on Oct. 14, 2020.
Original Filing: 301209449.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
H.R. 6800 - The Heroes Act
no specific bills, drug pricing and access, transparency, flu season
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 8337 - Continuing Appropriations Act of 2021
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on July 16, 2020.
Original Filing: 301189759.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
H.R. 6800 - The Heroes Act
no specific bills, drug pricing and access, transparency, flu season
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on April 15, 2020.
Original Filing: 301167138.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
no specific bills, drug pricing and access, transparency
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on Jan. 17, 2020.
Original Filing: 301109275.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019
no specific bills, drug pricing and access, transparency
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on Oct. 18, 2019.
Original Filing: 301069805.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B, international reference pricing, CMMI
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
no specific bills, drug pricing and access, transparency
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on July 19, 2019.
Original Filing: 301051726.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products, 340B
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, drug safety
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
no specific bills, drug pricing and access, transparency
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on April 22, 2019.
Original Filing: 301036114.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, PAHPA, antimicrobials, drug safety, Alzheimer's disease policies
no specific bills, drug pricing and access
Agencies Lobbied
U.S. Senate
Lobbying Issues
Appropriations
H.J.Res. 31 - Consolidated Appropriations Act, 2019
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009640.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation, combination products
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, PAHPA, antimicrobials, drug safety
S. 204/H.R. 878 - Right to Try
Agencies Lobbied
U.S. Senate
Lobbying Issues
Appropriations
H.R. 1625 - Consolidated Appropriations Act
H.R. 1892 - Bipartisan Budget Act
H.R. 6157 - HHS appropriations and continuing resolution
H.R. 695 - Department of Defense Appropriations Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $80,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997831.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D, innovation
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, PAHPA, antimicrobials, drug safety
S. 204/H.R. 878 - Right to Try
Agencies Lobbied
U.S. Senate
Lobbying Issues
Appropriations
H.R. 1625 - Consolidated Appropriations Act
H.R. 1892 - Bipartisan Budget Act
H.R. 6157 - HHS appropriations and continuing resolution
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Genentech, Inc. , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300976418.xml
Lobbying Issues
prescription drug access and affordability, coding, coverage, value based payments, biosimilars, Part B, Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B, PAHPA, antimicrobials, drug safety
S. 204/H.R. 878 - Right to Try
Agencies Lobbied
U.S. Senate
Lobbying Issues
Appropriations
H.R. 1625 - Consolidated Appropriations Act
H.R. 1892 - Bipartisan Budget Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
Tarplin, Downs & Young, LLC filed a lobbying registration on May 2, 2018 to represent Genentech, Inc., effective April 1, 2018.
Original Filing: 300959579.xml
Issue(s) they said they’d lobby about: 340B, CMS coverage and reimbursement, FDA policy .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...